Transcatheter Arterial Chemoembolization Plus ¹³¹I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
10.3348/kjr.2016.17.6.882
- Author:
Ze Xin ZHU
1
;
Ming Heng LIAO
;
Xiao Xue WANG
;
Ji Wei HUANG
Author Information
1. Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University, Chengdu 610041, China. huangjiweimd@hotmail.com
- Publication Type:Meta-Analysis ; Multicenter Study ; Randomized Controlled Trial ; Original Article
- Keywords:
¹³¹I-labelled metuximab;
Hepatocellular carcinoma;
Meta-analysis;
Transcatheter arterial chemoembolization;
Radioimmunotherapy
- MeSH:
Asian Continental Ancestry Group;
Atrophy;
Carcinoma, Hepatocellular*;
Humans;
Odds Ratio;
Prospective Studies;
Radioimmunotherapy
- From:Korean Journal of Radiology
2016;17(6):882-892
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The aim of the study was to compare transcatheter arterial chemoembolization (TACE) plus ¹³¹I-labelled metuximab with TACE alone for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A comprehensive search was conducted in PubMed, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Chinese BioMedical Literature Database with published date from the earliest to February 29th, 2016. No language restrictions were applied, but only prospective randomized controlled trials (RCTs) or non-RCTs were eligible for a full-text review. The primary outcome was the overall survival (OS) and effective rate (the rate of partial atrophy or complete clearance of the tumor lesion). The odds ratios (ORs) were combined using either the fixed-effects model or random-effects model. RESULTS: Eight trials (3 RCTs and 5 non-RCTs) were included, involving a total of 1121 patients. Patients receiving combined therapy of TACE plus ¹³¹I-labelled metuximab showed significant improvement in effective rate {OR = 4.00, (95% confidence interval [CI]: 2.40–6.66), p < 0.001}, 1-year OS (OR = 2.03 [95% CI: 1.55–2.67], p < 0.001) and 2-year OS (OR = 2.57 [95% CI: 1.41–4.66], p = 0.002]. CONCLUSION: TACE plus ¹³¹I-labelled metuximab is more beneficial for treating advanced HCCs than TACE alone in terms of tumor response and OS. Large, multi-center, and blinded randomized trials are required to confirm these findings.
